Does rosuvastatin affect kidney function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Rosuvastatin Affect Kidney Function?

Rosuvastatin does not cause clinically significant deterioration of kidney function in most patients, though it can cause benign proteinuria and hematuria, and carries a small increased risk of acute kidney injury in patients without pre-existing chronic kidney disease. 1, 2

Overall Renal Safety Profile

The evidence from guideline consensus demonstrates that rosuvastatin is generally safe for renal function:

  • In 72,488 patient-years of follow-up across 36 studies involving over 40,000 patients, renal impairment or failure occurred in only 536 participants (approximately 0.7% per year) 1
  • Rates of renal endpoints were higher in patients with baseline risk factors (hypertension, heart failure, diabetes, or eGFR <60 mL/min/1.73 m²), but there was no difference between placebo and rosuvastatin-treated patients, even in these high-risk groups 1
  • No difference was observed between the maximal 40 mg dose and 10 mg daily dose 1
  • Two meta-analyses showed no deterioration and a trend toward improvement or maintenance of renal function in patients with renal disease 1

Specific Renal Effects to Monitor

Proteinuria and Hematuria (Common but Benign)

The FDA label and guidelines acknowledge an established association with urinary findings:

  • Dipstick-positive proteinuria and microscopic hematuria occur more frequently with rosuvastatin, especially at the 40 mg dose 2
  • These findings are generally transient and not associated with worsening renal function 2
  • The mechanism is thought to be interference with tubular reabsorption of albumin, not indicative of true renal dysfunction 1
  • Recent real-world data from 152,101 rosuvastatin users showed 2.9% developed hematuria and 1.0% developed proteinuria over median 3.1 years follow-up 3

Clinical Action: Consider dose reduction if unexplained persistent proteinuria or hematuria develops during routine urinalysis 2

Acute Kidney Injury Risk (Context-Dependent)

There is contradictory evidence regarding acute kidney injury:

Observational data concerns:

  • A large retrospective study of >2 million patients found that high-potency statin users (including rosuvastatin 10 mg) were 34% more likely to be hospitalized with AKI within 120 days of starting treatment in patients WITHOUT chronic kidney disease 1
  • Paradoxically, patients WITH chronic kidney disease did not show as large an increase 1

However, these administrative database findings appear quite discordant with randomized trial data 1, which showed no increased risk. The guideline consensus emphasizes that the randomized trial evidence is more reliable.

Kidney Failure with Replacement Therapy

Recent real-world data comparing rosuvastatin to atorvastatin showed a modestly increased risk of KFRT (HR 1.15; 95% CI 1.02-1.30) 3, though the absolute risk remains low.

Dosing Recommendations by Renal Function

Per FDA labeling 2:

  • Mild to moderate renal impairment (CrCl ≥30 mL/min/1.73 m²): No dose adjustment needed
  • Severe renal impairment (CrCl <30 mL/min/1.73 m²) NOT on hemodialysis:
    • Start with 5 mg daily
    • Maximum dose 10 mg daily
    • Monitor for myopathy development
  • Dialysis patients: Guidelines suggest NOT initiating statins in prevalent dialysis patients, but continuing if already on therapy at dialysis initiation 4

Important Clinical Pitfall

A substantial 44% of patients with eGFR <30 mL/min/1.73 m² are prescribed high-dose rosuvastatin (20-40 mg daily), exceeding FDA recommendations 3. This represents a common prescribing error that increases risk of adverse effects including myopathy and potential renal complications.

Comparative Considerations

  • One study in diabetic patients suggested atorvastatin may have fewer detrimental effects on renal function than rosuvastatin (48.7% vs 38.6% rapid eGFR decline, p=0.029) 5
  • However, other studies showed rosuvastatin and atorvastatin both preserved renal function compared to omega-3 fatty acids in HIV patients with CKD 6
  • Rosuvastatin showed increased risk of hematuria (HR 1.08), proteinuria (HR 1.17), and KFRT (HR 1.15) compared to atorvastatin in large real-world analysis 3

Monitoring Approach

  • Baseline renal function assessment before initiation
  • Monitor for unexplained proteinuria or hematuria during routine urinalysis
  • If persistent urinary abnormalities develop, consider dose reduction 2
  • In patients with severe renal impairment, monitor closely for myopathy as renal dysfunction increases drug exposure 2
  • Do not routinely discontinue rosuvastatin for transient, asymptomatic proteinuria or hematuria unless persistent

Related Questions

Should rosuvastatin be dose-reduced for a patient with an estimated glomerular filtration rate of 55 mL/min/1.73 m²?
When and how should a high dose of rosuvastatin (Crestor) be initiated, monitored, and what are the contraindications?
When can rosuvastatin (Crestor) be started after cardiac surgery, what initial dose is recommended, and what monitoring is required?
Can rosuvastatin (Crestor) be dosed biweekly (every two weeks) instead of daily?
What is the recommended dosing for high‑intensity rosuvastatin, including dose adjustments for severe renal impairment and contraindications?
Is Zostum (cefoperazone + sulbactam) appropriate for a 9‑year‑old, 17‑kg boy with typical community‑acquired bacterial pneumonia?
What is the recommended approach to evaluate and treat fatigue in a middle‑aged adult (approximately 40–60 years old)?
What are the key differential diagnoses for an 85-year-old woman presenting with frequent band-like migraines, cognitive decline (brain fog), and restless legs?
Should a 67-year-old man with a normal echocardiogram, a 7‑day Holter showing frequent sinus tachycardia with episodes of nonsustained ventricular tachycardia lasting up to 6 hours 20 minutes and suspected atrial flutter, a history of coronary artery disease with prior percutaneous coronary intervention, and uncontrolled diabetes (hemoglobin A1c ≈13 %) be cleared for spinal surgery now, and should metoprolol be increased?
Is meropenem appropriate for a 9-year-old boy weighing 17 kg with typical community-acquired bacterial pneumonia?
What are the diagnostic criteria for hypotonia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.